[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100076696":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":7,"responsibleParty":7,"collaborators":7,"id":16,"slug":17,"hasResults":18,"nctId":19,"briefTitle":20,"officialTitle":21,"acronym":7,"eligibilityCriteria":22,"healthyVolunteers":18,"sex":23,"minAge":24,"maxAge":7,"enrollmentInfo":25,"targetDuration":7,"studyType":28,"phases":29,"briefSummary":31,"conditions":32,"keywords":35,"overallStatus":42,"whyStopped":7,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":7},{"fullName":5,"class":6},"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","galantamine hydrobromide",[13],{"name":14,"affiliation":5,"role":15},"Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial","STUDY_DIRECTOR","100076696","phase-3-a-study-of-the-safety-and-effectiveness-of-a-flexible-dose-of-galantamine-versus-placebo-in-the-treatment-of-patients-with-alzheimers-disease-100076696",false,"NCT00253227","A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease","Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial","Inclusion Criteria:\n\n* Outpatients with a diagnosis of Alzheimer's disease according to the National Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria (including patients living independently in residential homes for the elderly or day patients)\n* have mild to moderate dementia, as evidenced by a, Mini-Mental Status Examination (MMSE) score of 11 - 24, and a score of at least 12 on the cognitive portion of the Alzheimer's Disease Assessment scale (ADAS-cog)\n* history of at least 6 months of gradual and progressive cognitive decline\n* have a consistent informant to accompany the patient on scheduled visits\n\nExclusion Criteria:\n\n* Neurogenerative disorders such as Parkinson's disease\n* dementia caused by small strokes or cerebrovascular disease\n* cognitive impairment resulting from acute cerebral trauma, cerebral damage due to a lack of oxygen, vitamin deficiency, infections such as meningitis or AIDS, significant endocrine or metabolic disease, mental retardation or a brain tumor\n* having epilepsy, significant psychiatric disease, active peptic ulcer, clinically significant liver, kidney or lung disorders or heart disease\n* Females of child bearing potential without adequate contraception","ALL","18 Years",{"count":26,"type":27},387,"ACTUAL","INTERVENTIONAL",[30],"PHASE3","The purpose of this study is to evaluate the safety and effectiveness of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease using a flexible dose design.",[33,34],"Alzheimer Disease","Dementia",[36,37,38,39,40,41],"Alzheimer's disease","dementia","brain disease","memory loss","galantamine","placebo","COMPLETED","2011-05-17",{"date":45,"type":46},"2011-05-18","ESTIMATED",{"date":48,"type":7},"1997-07",{"date":50,"type":27},"1998-12",{"name":5,"class":6}]